Financial Data and Key Metrics Changes - The company reported net revenues of $785 million for Q4 2025, an increase of approximately 3% year-over-year, with Adjusted EBITDA of $88 million [6][19] - For the full year 2025, Branded Services generated $1 billion in revenues, down 9% year-over-year, and Adjusted EBITDA of $143 million, down 21% [19] - Experiential Services saw revenues of approximately $280 million in Q4, up 19% year-over-year, and Adjusted EBITDA of $28 million, up 115% [20] - Retailer Services reported Q4 revenues of $246 million, up 1%, but Adjusted EBITDA decreased by 22% year-over-year [22] Business Line Data and Key Metrics Changes - Experiential Services showed strong performance with a 15% increase in event volume and execution rates exceeding 93% [20][15] - Branded Services faced challenges due to sustained softness in CPG spending and client insourcing, impacting revenue and EBITDA negatively [19][15] - Retailer Services experienced project timing issues and cautious retail spending, leading to a mismatch in costs and revenue recognition [22][15] Market Data and Key Metrics Changes - Consumer behavior remains cautious, with lower-end consumers seeking promotions and higher-end consumers shifting to healthier options, affecting overall spending [9] - The company noted a pullback in traditional marketing as retailers demand more investment in their retail media networks [9] Company Strategy and Development Direction - The company is refinancing its debt to extend maturities to 2030, enhancing liquidity and operational flexibility [4][5] - A focus on divesting non-core businesses to streamline operations and redeploy capital into higher return opportunities [5] - The company is investing in IT transformation and technology to drive efficiencies and improve service delivery [10][12] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism for 2026, expecting revenue growth to be flat to low single digits, driven by Experiential Services and stabilization in Retailer Services [17][30] - Adjusted EBITDA is expected to be flat to down mid-single digits, reflecting ongoing macroeconomic headwinds and shifts towards lower-margin services [17][30] - The company anticipates unlevered free cash flow of approximately $250 million-$275 million for the year, supported by improved working capital management [30] Other Important Information - The company ended the year with $241 million in cash, bolstered by divestiture proceeds and improved working capital performance [25][26] - The net leverage ratio was approximately 4.4x Adjusted EBITDA, above the long-term target of 3.5x, with plans for debt paydown [25] Q&A Session Summary Question: On the debt exchange and its implications - Management acknowledged the increase in borrowing costs but emphasized the importance of extending the debt maturity to 2030 for operational flexibility [34][36] Question: Guidance on revenue and EBITDA growth - Management explained that high labor costs and business mix shifts are impacting margins, but they expect stabilization and improvements in the Branded Services segment over time [39][40] Question: Revenue expectations for 2026 - Management indicated that growth in Experiential Services and stabilization in Retailer Services would drive revenue growth, with Branded Services expected to improve gradually [48][49] Question: Impact of divestitures on revenue - Management confirmed that divestitures would impact revenue by approximately $20 million in 2025, with a corresponding EBITDA effect [56][57]

Advantage Solutions (NasdaqGS:ADV) Q4 2025 Earnings call March 03, 2026 08:30 AM ET Company ParticipantsChris Growe - CFODave Peacock - CEOGreg Parrish - VP of Equity ResearchLuke Morison - VP of Equity ResearchOperatorGreetings, welcome to the Advantage Solutions Fourth Quarter and Full Year 2025 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, si ...

Financial Data and Key Metrics Changes - For Q1 of fiscal 2026, total revenue was $120.9 million, a slight increase of $1 million or 0.8% from $119.9 million in Q1 of fiscal 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [12][19] - DSA revenue increased to $48 million from $42.8 million, representing a year-over-year growth of 12%, with discovery pharmacology service and surgical services contributing significantly [5][12] - RMS revenue decreased by $4.1 million or 5.4% to $72.9 million, primarily due to lower NHP volumes sold [14][15] - The overall operating loss increased to $16.3 million from $15.5 million, driven by a higher RMS operating loss [16][19] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in the prior year [18][19] Business Line Data and Key Metrics Changes - DSA business saw strong growth with net new awards of $53.6 million, a 27% increase over Q1 of fiscal 2025, and a trailing twelve-month increase of 34% [13] - DSA margins improved, with non-GAAP operating income for the DSA segment at $8.2 million or 6.8% of total revenue, up from $7.1 million or 5.9% [17] - RMS segment's non-GAAP operating income decreased to $7.2 million or 5.9% of total revenue, down from $9.4 million or 7.9% due to lower NHP volume sales [18] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA in Q1 of fiscal 2026 was 1.16 to 1, with a trailing twelve-month book-to-bill of 1.08 to 1 [14] - DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025 [14] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [10] - The company is enhancing its NAM strategy to support FDA guidance and industry expectations for innovation, with recent collaborations aimed at integrating advanced machine learning tools [10][50] - The company is committed to optimizing its operational footprint and product portfolio while maintaining client satisfaction [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the DSA business's momentum and the ongoing site optimization and cost reduction initiatives in the RMS business [9] - The company is navigating macroeconomic factors affecting the RMS business and remains committed to refinancing its debt and improving its balance sheet [9][20] - Management anticipates continued improvement in margins and revenue growth in the DSA segment as pricing stabilizes and operational efficiencies are realized [26][31] Other Important Information - The company engaged Perella Weinberg Partners for financial advisory services to explore debt refinancing alternatives [9] - Capital expenditures for Q1 of 2026 were $5.2 million, with expectations to keep annual CapEx below 4% of revenue [21][22] Q&A Session Summary Question: Can you provide more details on profitability and adjusted EBITDA trends? - Management noted that seasonality impacts the first quarter, and increased operating expenses were observed, particularly in cost of goods sold [25][26] Question: What is the outlook for DSA awards and growth? - Management highlighted that DSA growth is supported by improved customer relationships and scientific strength, with expectations for continued positive trends [28][30] Question: Can you explain the recent decline in RMS revenue and operating leverage? - Management indicated that reduced NHP volumes overshadowed operating leverage benefits, but cost reductions from facility closures are expected to yield improvements in future quarters [38][40] Question: How are recent weather conditions impacting operations and costs? - Management confirmed that weather impacts shipping and operations, but the overall cost impact is not significant [51][52]

Financial Data and Key Metrics Changes - For Q1 of fiscal 2026, total revenue was $120.9 million, a slight increase of $1 million or 0.8% from $119.9 million in Q1 of fiscal 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [12][19] - DSA revenue increased to $48 million from $42.8 million, reflecting a year-over-year growth of 12%, with discovery pharmacology service and surgical services contributing significantly [5][12] - RMS revenue for Q1 of fiscal 2026 was $72.9 million, a decrease of $4.1 million or 5.4% compared to the prior year, primarily due to lower NHP volumes sold [14][15] - The overall operating loss increased to $16.3 million from $15.5 million in the prior year, driven by an increase in RMS operating loss [16][19] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in Q1 of fiscal 2025 [18][19] Business Line Data and Key Metrics Changes - DSA business saw strong growth with net new awards of $53.6 million, a 27% increase over Q1 of fiscal 2025, and a 34% year-over-year increase for the trailing twelve-month period [13][19] - DSA margins improved, with non-GAAP operating income for the DSA segment at $8.2 million or 6.8% of total revenue, compared to $7.1 million or 5.9% in the prior year [17] - RMS segment reported non-GAAP operating income of $7.2 million or 5.9% of total revenue, down from $9.4 million or 7.9% in the prior year, primarily due to lower NHP volume sales [18] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA in Q1 of fiscal 2026 was 1.16 to 1, with a trailing twelve-month book-to-bill ratio of 1.08 to 1, indicating a healthy order intake relative to revenue [6][14] - DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025, and $130.4 million at December 31, 2024 [14] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [10][11] - The company is enhancing its NAM strategy to support FDA guidance and industry expectations for innovation, with recent collaborations aimed at integrating advanced machine learning tools [10][50] - The site optimization plan is expected to improve margins in future periods, with the current phase set to complete by Q3 of fiscal 2026 [7][9] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the DSA business's momentum and the ongoing site optimization and cost reduction initiatives in the RMS business [9][10] - The company is navigating macroeconomic factors affecting the RMS business and remains committed to refinancing its debt and improving its balance sheet [9][20] - Management noted that while the first quarter typically experiences seasonality challenges, they expect to see improvements in margins and revenue in the latter half of the fiscal year [26][28] Other Important Information - The company has received a waiver for non-compliance with financial covenant ratios under its credit agreement for Q1 of fiscal 2026 [9] - Capital expenditures in Q1 of 2026 were $5.2 million, with expectations for annual CapEx to remain below 4% of revenue [21][22] Q&A Session Summary Question: Can you provide more details on profitability and adjusted EBITDA trends? - Management acknowledged that margins in RMS impacted adjusted EBITDA, with some operational expenses higher than expected, and indicated that seasonality will likely follow previous patterns [25][26] Question: What is driving the positive trend in DSA awards? - Management attributed the growth in DSA awards to improved customer relationships, increased sales force efforts, and scientific strengths within the company [29][31] Question: What is the outlook for RMS operating leverage? - Management indicated that reduced NHP volumes overshadowed operating leverage benefits, but cost reductions from facility closures will contribute positively in future quarters [40][42] Question: How much was NHP volume down year-over-year? - Management reported that NHP volumes were down approximately 25% year-over-year [44][45] Question: Can you elaborate on new relationships in the NAM space? - Management highlighted ongoing R&D efforts and collaborations aimed at innovation, which are expected to drive incremental revenues [49][50]

Financial Data and Key Metrics Changes - Total revenue for Q1 2026 was $120.9 million, a slight increase of $1 million or 0.8% compared to $119.9 million in Q1 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [11][18] - DSA revenue increased to $48 million from $42.8 million, reflecting a year-over-year growth of 12% [5][11] - RMS revenue decreased by 5.4% to $72.9 million, primarily due to lower NHP volumes sold [7][13] - The overall operating loss increased to $16.3 million from $15.5 million, driven by a higher RMS operating loss [14][18] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in Q1 2025 [17][18] Business Line Data and Key Metrics Changes - DSA business saw strong growth with discovery awards up 44% and safety assessment awards up 22% year-over-year [6] - DSA margins improved, achieving the strongest first quarter margins in three years [6][15] - RMS services revenue grew by 13% compared to Q1 2025, mainly due to higher NHP colony management services revenue [7][13] - The book-to-bill ratio for DSA was 1.16 to 1 for the quarter and 1.08 to 1 for the trailing twelve months [6][13] Market Data and Key Metrics Changes - The DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025 [13] - The conversion rate for DSA backlog was 33.2%, slightly up from 32.8% in the prior year [12] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [9] - Continued emphasis on innovation through collaborations that integrate machine learning tools and enhance data analysis capabilities [9][50] - The company is committed to optimizing its operational footprint and enhancing client satisfaction [10][57] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in the RMS business due to macroeconomic factors and lower NHP sales, but expressed optimism about future improvements in margins [8][9] - The company plans to resume providing financial guidance once there is greater clarity on market demand and tariff impacts [20][21] - Management remains confident in the company's strategic direction and ongoing improvements in financial performance [57] Other Important Information - The company engaged Perella Weinberg Partners for financial advisory services to explore debt refinancing alternatives [8] - Capital expenditures for Q1 2026 were $5.2 million, with expectations to keep annual CapEx below 4% of revenue [20] Q&A Session Questions and Answers Question: Can you provide more detail on profitability and adjusted EBITDA trends? - Management indicated that seasonality impacts the first quarter, and increased operating expenses were noted, particularly in cost of goods sold [23][25] Question: What is the outlook for DSA awards and growth? - Management highlighted that DSA growth is supported by improved customer relationships and scientific capabilities, contributing to increased recurring sales [28][30] Question: How will the recent lease exits impact operating costs? - Management confirmed that lease exits will lead to additional cost reductions in the upcoming quarters, although current volume reductions in NHPs overshadowed some operating leverage benefits [38][40]

Core Viewpoint - The company, 澳博控股 (Amax Holdings), has announced the listing of its 2026 notes on the Hong Kong Stock Exchange, with a total principal amount of $500 million still outstanding [1] Group 1: Purchase Offer - The issuer of the 2026 notes is making a cash purchase offer to buy any and all validly delivered 2026 notes at a purchase price of $1,000 per $1,000 principal amount, subject to the terms and conditions outlined in the offer [1] - The purchase offer aims to acquire the total principal amount of the issued 2026 notes as part of the refinancing of the company's existing debt [1] Group 2: Management and Advisory - Deutsche Bank's Singapore branch is acting as the exclusive dealer manager for the offer, while Kroll Issuer Services Limited is serving as the information and delivery agent for the offer [1] Group 3: New Notes Issuance - SJM International Limited, a wholly-owned subsidiary of the company, is concurrently launching a priority note issuance guaranteed by the company, referred to as "synchronized new funding issuance" [1] - The synchronized new funding issuance is not part of the purchase offer and is conducted under a separate offering memorandum [1] - The offer is subject to several conditions, including the successful completion of the synchronized new funding issuance [1]

Core Viewpoint - The company plans to issue international notes through its wholly-owned subsidiary, aimed at non-U.S. persons outside the United States, under Regulation S of the U.S. Securities Act [1] Group 1 - The company will hold a series of fixed-income investor meetings and conference calls starting on or around January 5, 2026 [1] - The notes, if issued, will be backed by an irrevocable and unconditional guarantee provided by the company [1] - The net proceeds from the proposed issuance are intended for refinancing existing debt and general corporate purposes [1]

Core Insights - DXP Enterprises successfully completed a refinancing of $848 million, which includes $643 million in existing Term Loan B borrowings and an additional $205 million, aimed at enhancing liquidity and flexibility for growth [1] - The refinancing is expected to generate approximately $3.2 million in annual interest savings, allowing for strategic reinvestment and potential acquisitions [1] - DXP's sales have increased from $1.0 billion in 2020 to $1.96 billion for the twelve months ending September 30, 2025, with adjusted EBITDA rising from $64.9 million to over $225 million during the same period [1] - The company's pro forma net debt to EBITDA ratio stands at 2.8:1 following the refinancing [1] Company Overview - DXP Enterprises, Inc. is a leading distributor of products and services, providing value-added solutions to industrial customers across the United States, Canada, Mexico, and Dubai [1] - The company specializes in innovative pumping solutions, supply chain services, and maintenance, repair, operating, and production (MROP) services, leveraging extensive product knowledge and technical expertise [1] - DXP's business segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services, which create competitive advantages for customers [1]

Financial Data and Key Metrics Changes - For Q4 fiscal 2025, total revenue was $138.1 million, an increase of $7.7 million or 5.9% compared to Q4 fiscal 2024, primarily driven by the DSA segment [9][18] - For fiscal year 2025, total revenue was $513 million, an increase of $22.3 million or 4.5% compared to $490.7 million for fiscal 2024 [9][18] - The overall operating loss for Q4 fiscal 2025 decreased to $6.8 million from $13.2 million in Q4 fiscal 2024 [22] - Consolidated net loss attributable to common shareholders for Q4 fiscal 2025 was $8.6 million or a $0.25 loss per diluted share, compared to a loss of $18.9 million or $0.73 per diluted share in Q4 fiscal 2024 [26] Business Line Data and Key Metrics Changes - DSA revenue for Q4 fiscal 2025 was $51.6 million, a 15.7% increase year-over-year, driven by discovery and translational science services [19] - RMS revenue for Q4 fiscal 2025 was $86.5 million, an increase of $700,000 or 0.8% compared to Q4 fiscal 2024 [21] - DSA backlog was $138.2 million at September 30, 2025, compared to $129.9 million at September 30, 2024 [19] Market Data and Key Metrics Changes - The DSA backlog conversion rate was 37.4% for Q4 fiscal 2025, the highest quarterly conversion rate in three years [11] - Net new DSA Awards for Q4 fiscal 2025 were $54.2 million, a 61% increase over Q4 fiscal 2024 [20] Company Strategy and Development Direction - The company aims to improve cash flow and margins while focusing on customer metrics, with specific goals to enhance DSA revenue and margins [7] - The RMS site consolidation project is on track, with plans to close a total of 13 RMS facilities, which is expected to yield annual savings of $6 million to $7 million [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds from a cybersecurity incident but expressed satisfaction with the recovery and ongoing demand trends [8][33] - The company is optimistic about maintaining revenue growth and improving margins, with a focus on cost reduction in the RMS business [39][40] Other Important Information - The company engaged Perella Weinberg Partners for financial advisory services to explore potential debt refinancing alternatives [8] - Cash balance increased to $21.7 million as of September 30, 2025, compared to $6.2 million at June 30, 2025 [16][27] Q&A Session Summary Question: What were the headwinds faced in the quarter? - Management identified a cybersecurity incident as the major headwind, leading to increased costs and operational challenges [33][34] Question: What are the quarter-to-date trends regarding ordering patterns? - Management noted that the upcoming quarter is typically weaker due to holiday seasonality but expressed optimism based on recent revenue increases [38][39] Question: How is the company positioned regarding FDA guidance on animal models? - Management indicated minimal exposure to monoclonal antibodies and does not foresee significant impacts from the FDA's guidance [44][45] Question: What are the expectations for customer budgets in 2026? - Management observed an increase in quoting activity and expressed optimism about potential revenue growth for the next year [46][48] Question: How quickly can studies start for clients? - The company typically starts smaller studies within weeks, while larger animal safety assessments may take three to nine months [52]

Financial Data and Key Metrics Changes - For Q4 fiscal 2025, total revenue was $138.1 million, an increase of $7.7 million or 5.9% compared to Q4 fiscal 2024, primarily driven by the DSA segment [9][18] - For fiscal year 2025, total revenue was $513 million, an increase of $22.3 million or 4.5% compared to $490.7 million for fiscal 2024 [9][18] - The overall operating loss for Q4 fiscal 2025 decreased to $6.8 million from $13.2 million in Q4 fiscal 2024 [21] - Consolidated net loss attributable to common shareholders in Q4 fiscal 2025 totaled $8.6 million or a $0.25 loss per diluted share, compared to a loss of $18.9 million or $0.73 per diluted share in Q4 fiscal 2024 [26] Business Line Data and Key Metrics Changes - DSA revenue for Q4 fiscal 2025 was $51.6 million, a 15.7% increase year-over-year, driven by discovery and translational science services [19][20] - RMS revenue for Q4 fiscal 2025 was $86.5 million, an increase of $700,000 or 0.8% compared to Q4 fiscal 2024 [20] - DSA backlog was $138.2 million at September 30, 2025, compared to $129.9 million at September 30, 2024 [19] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA for Q4 fiscal 2025 was 1.08 to 1, indicating strong demand [19] - DSA cancellations and negative change orders in Q4 fiscal 2025 were approximately 29% lower compared to the prior year [20] Company Strategy and Development Direction - The company aims to improve DSA revenue and margins while continuing RMS site consolidation to reduce costs [6][9] - The plan includes closing 13 RMS facilities over three years to modernize operations and improve efficiency [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged headwinds from a cybersecurity incident but expressed satisfaction with the recovery and ongoing demand [7][16] - The company remains optimistic about maintaining revenue growth and improving margins in the upcoming quarters [37][41] Other Important Information - The company engaged Perella Weinberg Partners for financial advisory services to explore debt refinancing alternatives [8] - Cash from operations in Q4 fiscal 2025 was $14.3 million, increasing the cash balance to $21.7 million [16][27] Q&A Session Summary Question: What were the headwinds faced in the quarter? - The major headwind was a cybersecurity incident that caused additional expenses and operational challenges, though the company managed to achieve significant awards despite this [31][32] Question: What are the quarter-to-date trends regarding ordering patterns? - The company typically sees a slowdown during the holiday season, but recent quoting activity has been encouraging, with a focus on cost reduction in the RMS business [35][36] Question: How is the company positioned regarding FDA guidance on animal models? - The company has minimal exposure to monoclonal antibodies and does not anticipate significant impacts from the FDA's new guidance [39][40] Question: What are the expectations for customer budgets in the upcoming year? - The company is seeing an increase in quoting activity and anticipates a substantial increase in bookings, indicating a positive outlook for next year's budgets [41] Question: How quickly can studies start for clients? - The company can typically start smaller studies within weeks, while larger animal safety assessments may take three to nine months [42]